How did you decide to participate in the Biomapas Academy?
When I used to walk past a pharmacy every day, I could never stop dreaming about being able to help people and develop innovative pharmaceuticals. So while studying biomedical sciences, I became interested in the drug development paths, which led me to medicinal chemistry. And one day at the university, I saw a poster about the Biomapas Academy, which could help me understand what, how, where, and when happens to pharmaceutical products during the whole journey to reach us, so I signed up for it without hesitation. Even though I am usually not a lucky person, I was selected to be one of the participants, which surprised me!
How was your experience regarding the Academy?
During the few months, I deepened my existing knowledge of drug development stages and expanded it to learn more about drug regulation and pharmacovigilance. After graduating from the Academy, I got the opportunity to try out regulatory affairs as part of Biomapas – I completed a summer internship in the Regulatory Affairs department.
How do you feel after graduating from the Academy?
I will never forget this practice in my life, not only because it fulfilled what I was looking for, but it let me realize that I want to return to this company after my graduation and put my accumulated knowledge to use. Thanks again to all Biomapas staff for their insights and advice, and I hope to see you soon.
Biomapas Academy
What is Clinical Research? Regulatory Affairs? Pharmacovigilance?
Global Case Processing in Pharmacovigilance: Practical Guide to Compliance, Quality, and Scale
As pharmacovigilance expands across markets, maintaining control becomes challenging. In this article, we explore key risks, regulatory differences, and scalable models for global case processing.
Case Study: International & Local Pharmacovigilance/Medical Information Services – Urgent Action
Discover how Biomapas delivered a seamless global and local transition for a pharmaceutical company, facing a critical Pharmacovigilance and Medical Information vendor transition with a non‑negotiable one‑month timeline.
Marketing Pharmaceutical Products in CIS/Eurasian Economic Union
Explore how pharmaceutical companies can successfully market products in CIS and EAEU countries, highlighting regulatory differences from the EU, recent legislative changes, and practical RA and pharmacovigilance considerations.
Partial Pharmacovigilance Outsourcing: A Scalable Approach for Biopharma
Learn how partial pharmacovigilance outsourcing helps biopharma maintain oversight while scaling resources effectively.
Pharmacovigilance and Medical Information Outsourcing: Benefits for Biotech
Learn how PV and MI outsourcing enables biotechs to reduce costs, scale efficiently, strengthen compliance, and accelerate market readiness.
Biomapas Insights: Clinical Site Selection for Early Phase Oncology Studies
Expert perspectives on where to begin, how to choose the right clinical sites, and what to consider when selecting an eCRF/EDC system for early-phase oncology studies.
Case Study: Specialised Rescue Studies in Georgia
Discover how we successfully supported late‑phase clinical trials in Georgia by overcoming operational constraints, accelerating study start‑up, and restoring delivery confidence in complex research environments. This case study highlights three real‑world success...
Comprehensive Guide to Medical Information and Pharmacovigilance Integration
Discover how integrated Medical Information and Pharmacovigilance workflows enhance compliance, improve safety, and streamline regulatory processes.
Biomapas Insights: From Hope to Global Impact – How Elpida Accelerated Gene Therapy for Rare Diseases
In this Biomapas Insights episode, Martijn van de Leur, Chief Commercial Officer, speaks with Terry Pirovolakis, CEO of Elpida Therapeutics, the organisation that grew out of the CureSPG50 advocacy movement. Together, they explore how a parent-led mission to help...
Biomapas Insights: Selecting the Right CRO at the right time – What Biotechs Need to Know
Expert insights on timing, selection criteria, and early-phase clinical trial strategy for choosing the right CRO in biotech development.
